These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

509 related items for PubMed ID: 7925820

  • 21. Evidence for a protective action of the vigilance promoting drug modafinil on the MPTP-induced degeneration of the nigrostriatal dopamine neurons in the black mouse: an immunocytochemical and biochemical analysis.
    Fuxe K, Janson AM, Rosén L, Finnman UB, Tanganelli S, Morari M, Goldstein M, Agnati LF.
    Exp Brain Res; 1992; 88(1):117-30. PubMed ID: 1347270
    [Abstract] [Full Text] [Related]

  • 22. Involvement of cytochrome P450 2E1 in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse model of Parkinson's disease.
    Vaglini F, Pardini C, Viaggi C, Bartoli C, Dinucci D, Corsini GU.
    J Neurochem; 2004 Oct; 91(2):285-98. PubMed ID: 15447662
    [Abstract] [Full Text] [Related]

  • 23. Modeling early Parkinson's disease pathology with chronic low dose MPTP treatment.
    Korecka JA, Eggers R, Swaab DF, Bossers K, Verhaagen J.
    Restor Neurol Neurosci; 2013 Oct; 31(2):155-67. PubMed ID: 23271419
    [Abstract] [Full Text] [Related]

  • 24. Damage to the nigrostriatal system in the MPTP-treated SAMP8 mouse.
    Liu J, Wang YY, Liu L, Wang QD, Yuan ZY, Zhang ZX, Gu P, Wang MW.
    Neurosci Lett; 2008 Dec 26; 448(2):184-8. PubMed ID: 18977411
    [Abstract] [Full Text] [Related]

  • 25. Embryonic ventral mesencephalic grafts to the substantia nigra of MPTP-treated monkeys: feasibility relevant to multiple-target grafting as a therapy for Parkinson's disease.
    Collier TJ, Sortwell CE, Elsworth JD, Taylor JR, Roth RH, Sladek JR, Redmond DE.
    J Comp Neurol; 2002 Jan 21; 442(4):320-30. PubMed ID: 11793337
    [Abstract] [Full Text] [Related]

  • 26. Absence of inclusion body formation in the MPTP mouse model of Parkinson's disease.
    Shimoji M, Zhang L, Mandir AS, Dawson VL, Dawson TM.
    Brain Res Mol Brain Res; 2005 Mar 24; 134(1):103-8. PubMed ID: 15790534
    [Abstract] [Full Text] [Related]

  • 27. Dietary restriction affects striatal glutamate in the MPTP-induced mouse model of nigrostriatal degeneration.
    Holmer HK, Keyghobadi M, Moore C, Menashe RA, Meshul CK.
    Synapse; 2005 Aug 24; 57(2):100-12. PubMed ID: 15906381
    [Abstract] [Full Text] [Related]

  • 28. Estrogen attenuates the MPTP-induced loss of dopamine neurons from the mouse SNc despite a lack of estrogen receptors (ERalpha and ERbeta).
    Shughrue PJ.
    Exp Neurol; 2004 Dec 24; 190(2):468-77. PubMed ID: 15530885
    [Abstract] [Full Text] [Related]

  • 29. Neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the substantia nigra and the locus coeruleus in BALB/c mice.
    Hu SC, Chang FW, Sung YJ, Hsu WM, Lee EH.
    J Pharmacol Exp Ther; 1991 Dec 24; 259(3):1379-87. PubMed ID: 1684822
    [Abstract] [Full Text] [Related]

  • 30. Differences between subacute and chronic MPTP mice models: investigation of dopaminergic neuronal degeneration and alpha-synuclein inclusions.
    Gibrat C, Saint-Pierre M, Bousquet M, Lévesque D, Rouillard C, Cicchetti F.
    J Neurochem; 2009 Jun 24; 109(5):1469-82. PubMed ID: 19457163
    [Abstract] [Full Text] [Related]

  • 31. Gender differences on MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity in C57BL/6 mice.
    Ookubo M, Yokoyama H, Kato H, Araki T.
    Mol Cell Endocrinol; 2009 Nov 13; 311(1-2):62-8. PubMed ID: 19631714
    [Abstract] [Full Text] [Related]

  • 32. Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), a radical scavenger, prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in the substantia nigra but not the striatum.
    Kawasaki T, Ishihara K, Ago Y, Baba A, Matsuda T.
    J Pharmacol Exp Ther; 2007 Jul 13; 322(1):274-81. PubMed ID: 17429058
    [Abstract] [Full Text] [Related]

  • 33. The TrkB-positive dopaminergic neurons are less sensitive to MPTP insult in the substantia nigra of adult C57/BL mice.
    Ding YX, Xia Y, Jiao XY, Duan L, Yu J, Wang X, Chen LW.
    Neurochem Res; 2011 Oct 13; 36(10):1759-66. PubMed ID: 21562748
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Effects of blocking the dopamine biosynthesis and of neurotoxic dopamine depletion with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on voluntary wheel running in mice.
    Leng A, Mura A, Hengerer B, Feldon J, Ferger B.
    Behav Brain Res; 2004 Oct 05; 154(2):375-83. PubMed ID: 15313025
    [Abstract] [Full Text] [Related]

  • 36. Overexpression of Parkinson's disease-associated alpha-synucleinA53T by recombinant adeno-associated virus in mice does not increase the vulnerability of dopaminergic neurons to MPTP.
    Dong Z, Ferger B, Feldon J, Büeler H.
    J Neurobiol; 2002 Oct 05; 53(1):1-10. PubMed ID: 12360578
    [Abstract] [Full Text] [Related]

  • 37. Protocatechuic acid inhibits neurotoxicity induced by MPTP in vivo.
    Zhang HN, An CN, Zhang HN, Pu XP.
    Neurosci Lett; 2010 Apr 26; 474(2):99-103. PubMed ID: 20227465
    [Abstract] [Full Text] [Related]

  • 38. Correlation between the neostriatal content of the 1-methyl-4-phenylpyridinium species and dopaminergic neurotoxicity following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration to several strains of mice.
    Giovanni A, Sieber BA, Heikkila RE, Sonsalla PK.
    J Pharmacol Exp Ther; 1991 May 26; 257(2):691-7. PubMed ID: 2033514
    [Abstract] [Full Text] [Related]

  • 39. Resveratrol, a red wine polyphenol, protects dopaminergic neurons in MPTP-treated mice.
    Blanchet J, Longpré F, Bureau G, Morissette M, DiPaolo T, Bronchti G, Martinoli MG.
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Jul 01; 32(5):1243-50. PubMed ID: 18471948
    [Abstract] [Full Text] [Related]

  • 40. Quantification of MPTP-induced dopaminergic neurodegeneration in the mouse substantia nigra by laser capture microdissection.
    Stephenson D, Ramirez A, Long J, Barrezueta N, Hajos-Korcsok E, Matherne C, Gallagher D, Ryan A, Ochoa R, Menniti F, Yan J.
    J Neurosci Methods; 2007 Jan 30; 159(2):291-9. PubMed ID: 16949674
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 26.